William Blair has lowered its third-quarter 2025 earnings forecast for Jasper Therapeutics to a loss of $0.75 per share, according to an analyst note issued on August 14. The deeper-than-expected projection, reported by Defenseworld.net, signals mounting challenges for the California-based biotech firm.